As in PCa, mutations of the pioneer transcription factor FOXA1 are common in ER+ breast cancer, and mutation of FOXA1 can alter its function and correlate strongly with endocrine therapy sensitivity [105]. Here, FOXA1 is linked to breast carcinoma.